Safety Profile
Known Safety Concerns
- Manganism (Parkinson-like neurotoxicity) with chronic excess
- Brain preferentially accumulates manganese -- CNS toxicity risk
- UL 11 mg per day
- Neurodevelopmental concerns in children with excess intake
Contraindications
- Manganism (Parkinson-like neurotoxicity) with chronic excess
- Brain preferentially accumulates manganese -- CNS toxicity risk
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Manganese gluconate is an organic chelated form of manganese with good bioavailability, commonly used in supplements. Manganese is essential but the brain preferentially accumulates it, making chronic excess neurotoxic. Manganism (Parkinson-like syndrome) is associated with chronic elevated manganese exposure. UL is 11 mg per day. Most people receive adequate manganese from diet.
Biological and Chemical Classification
- Scientific Name
- Manganese gluconate
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 5 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Mineral
- Evidence consistency: High consistency across studies (100%)
- Manganism (Parkinson-like neurotoxicity) with chronic excess
- Brain preferentially accumulates manganese -- CNS toxicity risk
- UL 11 mg per day
- Neurodevelopmental concerns in children with excess intake
The available scientific evidence for Manganese Gluconate indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 5/40 |
| Evidence consistency | 20/20 |
| Safety signals | 10/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 5 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 5 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 01 მაი 2026, 16:22
Evidence Distribution
-
Observational / other LOW evidence YELLOWEarly Haematologic Response to Oral Iron Treatment in Adults With Moderate Iron-Deficiency Anaemia. ↗Cacoub P et al.. Early Haematologic Response to Oral Iron Treatment in Adults With Moderate Iron-Deficiency Anaemia.. Anemia. 2025. PMID:41277915.PMID 41277915 ↗Journal AnemiaYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41277915/
-
Observational / other LOW evidence YELLOWNovel Use of Manganese Gluconate as a Marker for Visualization of Tablet Dissolution in the Fed Human Stomach Using Magnetic Resonance Imaging. ↗Akbar T et al.. Novel Use of Manganese Gluconate as a Marker for Visualization of Tablet Dissolution in the Fed Human Stomach Using Magnetic Resonance Imaging.. Mol Pharm. 2025. PMID:39637400.PMID 39637400 ↗Journal Mol PharmYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39637400/
-
Observational / other LOW evidence YELLOWIs there a fast track ("Darmstrasse") for fluids in the small intestine? Evidence from magnetic resonance imaging. ↗Großmann L et al.. Is there a fast track ("Darmstrasse") for fluids in the small intestine? Evidence from magnetic resonance imaging.. Eur J Pharm Biopharm. 2024. PMID:38582180.PMID 38582180 ↗Journal Eur J Pharm BiopharmYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38582180/
-
Observational / other LOW evidence YELLOWThe promising performance of manganese gluconate as a liquid redox sulfur recovery agent against oxidative degradation. ↗Widodo A et al.. The promising performance of manganese gluconate as a liquid redox sulfur recovery agent against oxidative degradation.. Heliyon. 2021. PMID:33937541.PMID 33937541 ↗Journal HeliyonYear 2021Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/33937541/
-
Observational / other LOW evidence YELLOWManganese gluconate, A greener and more degradation resistant agent for H(2)S oxidation using liquid redox sulfur recovery process. ↗Prakoso T et al.. Manganese gluconate, A greener and more degradation resistant agent for H(2)S oxidation using liquid redox sulfur recovery process.. Heliyon. 2020. PMID:33869815.PMID 33869815 ↗Journal HeliyonYear 2020Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/33869815/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Manganese Gluconate. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Manganese Gluconate
A score of 3.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.